Twinbeech Capital LP purchased a new position in shares of InMode Ltd. (NASDAQ:INMD - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 19,677 shares of the healthcare company's stock, valued at approximately $329,000.
Other institutional investors have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new position in InMode in the 4th quarter valued at about $87,000. Farther Finance Advisors LLC boosted its position in InMode by 26.2% in the 4th quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company's stock valued at $93,000 after buying an additional 1,154 shares during the last quarter. Covestor Ltd boosted its position in InMode by 13.9% in the 4th quarter. Covestor Ltd now owns 5,936 shares of the healthcare company's stock valued at $99,000 after buying an additional 723 shares during the last quarter. Lazard Asset Management LLC boosted its position in InMode by 6,128.7% in the 4th quarter. Lazard Asset Management LLC now owns 6,291 shares of the healthcare company's stock valued at $105,000 after buying an additional 6,190 shares during the last quarter. Finally, Pilgrim Partners Asia Pte Ltd purchased a new position in InMode in the 4th quarter valued at about $114,000. 68.04% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on the stock. Robert W. Baird lowered shares of InMode from an "outperform" rating to a "neutral" rating and cut their target price for the company from $22.00 to $16.00 in a research note on Monday, April 28th. Needham & Company LLC restated a "hold" rating on shares of InMode in a research note on Monday, April 28th. Baird R W lowered shares of InMode from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 28th. UBS Group cut their target price on shares of InMode from $19.00 to $16.25 and set a "neutral" rating on the stock in a research note on Tuesday, April 29th. Finally, BTIG Research lowered shares of InMode from a "buy" rating to a "neutral" rating in a research note on Tuesday, April 29th. Seven equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $18.54.
View Our Latest Stock Analysis on INMD
InMode Stock Performance
Shares of NASDAQ:INMD traded down $0.06 during mid-day trading on Wednesday, hitting $14.49. The stock had a trading volume of 196,136 shares, compared to its average volume of 1,232,250. The company has a market cap of $915.58 million, a PE ratio of 6.16 and a beta of 2.02. InMode Ltd. has a 12-month low of $13.68 and a 12-month high of $19.85. The company's 50 day moving average is $15.44 and its 200-day moving average is $17.15.
InMode (NASDAQ:INMD - Get Free Report) last issued its quarterly earnings results on Monday, April 28th. The healthcare company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.14). The firm had revenue of $77.87 million during the quarter, compared to analysts' expectations of $82.21 million. InMode had a net margin of 45.91% and a return on equity of 18.25%. The firm's revenue was down 3.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.32 EPS. On average, equities research analysts predict that InMode Ltd. will post 1.75 EPS for the current fiscal year.
InMode Company Profile
(
Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Further Reading
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
